Evaluation of immunohistochemistry using two different antibodies and procedures for primary lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangement

Akiba,Jun; Kawahara,Akihiko; Abe,Hideyuki; Azuma,Koichi; Yamaguchi,Tomohiko; Taira,Tomoki; Fukumitsu,Chihiro; Takase,Yorihiko; Yasumoto,Makiko; Umeno,Yumi; Todoroki,Keita; Kurita,Takashi; Yamaguchi,Rin; Kage,Masayoshi; Yano,Hirohisa

doi:10.3892/ol.2014.2511

Evaluation of immunohistochemistry using two different antibodies and procedures for primary lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangement

Authors:
- Jun Akiba
- Akihiko Kawahara
- Hideyuki Abe
- Koichi Azuma
- Tomohiko Yamaguchi
- Tomoki Taira
- Chihiro Fukumitsu
- Yorihiko Takase
- Makiko Yasumoto
- Yumi Umeno
- Keita Todoroki
- Takashi Kurita
- Rin Yamaguchi
- Masayoshi Kage
- Hirohisa Yano
View Affiliations

Affiliations: Department of Pathology, Division of Respirology, Neurology, and Rheumatology, Kurume University School of Medicine, Kurume, Fukuoka 830‑0011, Japan, Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Fukuoka 830‑0011, Japan, Department of Internal Medicine, Division of Respirology, Neurology, and Rheumatology, Kurume University School of Medicine, Kurume, Fukuoka 830‑0011, Japan
Published online on: September 8, 2014 https://doi.org/10.3892/ol.2014.2511
Pages: 2155-2159

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Rearrangements of anaplastic lymphoma kinase (ALK) have been recently identified in non‑small cell lung carcinomas. Previous studies have revealed characteristic features, including adenocarcinoma histology and mucin production, in ALK‑positive lung carcinoma. The present study evaluated immunohistochemistry (IHC) in ALK‑positive lung carcinoma using two different antibodies, clone 5A4 and D5F3, and compared the results. On the basis of the aforementioned characteristic features, out of 359 primary lung carcinomas, the ALK status of 14 adenocarcinomas was screened using the intercalated antibody‑enhanced polymer (iAEP) method with antibody 5A4, and this was compared with the ALK status obtained using rabbit monoclonal antibody D5F3 and fluorescence in situ hybridization for ALK. Eight cases were demonstrated to be ALK‑positive by IHC. Seven cases exhibited ALK rearrangement, which was demonstrated by fluorescence in situ hybridization. The IHC for ALK obtained using D5F3 was comparable with that of the iAEP and exhibited low heterogeneity. This finding suggests that IHC for ALK could be useful in limited tissue samples, such as biopsy specimens or cytology, for the screening of ALK‑positive lung carcinoma. In the present study, it was demonstrated that IHC with ALK monoclonal antibody D5F3 was useful for screening lung adenocarcinoma harboring ALK rearrangement.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
2	Travis WD, Brambilla E, Noguchi M, et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 6:244–285. 2011.
3	Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol. 21:2237–2246. 2003.
4	Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
5	Azzoli CG, Baker S Jr, Temin S, et al: American Society of Clinical Oncology: American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 27:6251–6266. 2009.
6	Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004.
7	Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 448:561–566. 2007.
8	Rodig SJ, Mino-Kenudson M, Dacic S, et al: Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 15:5216–5223. 2009.
9	Shaw AT, Yeap BY, Mino-Kenudson M, et al: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 27:4247–4253. 2009.
10	Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 363:1693–1703. 2010.
11	Takahashi T, Sonobe M, Kobayashi M, et al: Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 17:889–897. 2010.
12	Yoshida A, Tsuta K, Nakamura H, et al: Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol. 35:1226–1234. 2011.
13	Wong DW, Leung EL, So KK, et al: University of Hong Kong Lung Cancer Study Group: The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 115:1723–1733. 2009.
14	Christensen JG, Zou HY, Arango ME, et al: Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 6:3314–3322. 2007.
15	Takeuchi K, Choi YL, Togashi Y, et al: KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 15:3143–3149. 2009.
16	Yi ES, Boland JM, Maleszewski JJ, et al: Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol. 6:459–465. 2011.
17	FDA. FDA summary of safety and effectiveness data. http://www.accessdata.fda.gov/cdrh_docs/pdf11/p110012b.pdf. Accessed August 26, 2011
18	Baselga E, Torrelo A, Drolet BA, Zambrano A, Alomar A and Esterly NB: Familial nonmembranous aplasia cutis of the scalp. Pediatr Dermatol. 22:213–217. 2005.
19	Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ and Weeks JC: HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol. 22:854–863. 2004.
20	Gouvêa AP, Milanezi F, Olson SJ, Leitao D, Schmitt FC and Gobbi H: Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas. Appl Immunohistochem Mol Morphol. 14:103–108. 2006.
21	Roche PC, Suman VJ, Jenkins RB, et al: Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst. 94:855–857. 2002.
22	Vance GH, Barry TS, Bloom KJ, et al: College of American Pathologists: Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med. 133:611–612. 2009.
23	Allred DC and Swanson PE: Testing for erbB-2 by immunohistochemistry in breast cancer. Am J Clin Pathol. 113:171–175. 2000.
24	Conklin CM, Craddock KJ, Have C, Laskin J, Couture C and Ionescu DN: Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol. 8:45–51. 2013.
25	Mino-Kenudson M, Chirieac LR, Law K, et al: A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 16:1561–1571. 2010.
26	Park HS, Lee JK, Kim DW, et al: Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer. 77:288–292. 2012.
27	Li Y, Pan Y, Wang R, et al: ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR. PLoS One. 8:e690162013.
28	Kawahara A, Akiba J, Abe H, et al: Eml4-alk-positive lung adenocarcinoma with signet-ring cells. Diagn Cytopathol. 42:460–463. 2014.
29	Takamochi K, Takeuchi K, Hayashi T, Oh S and Suzuki K: A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: a comprehensive study of surgically treated Japanese patients. PLoS One. 8:e697942013.
30	Selinger CI, Rogers TM, Russell PA, et al: Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 26:1545–1553. 2013.
31	Lindeman NI, Cagle PT, Beasley MB, et al: Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 137:828–860. 2013.